Related Experiment Video
Updated: Nov 1, 2025

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease
Published on: January 29, 2021
Therapeutic Experience of Progressive Multifocal Leukoencephalopathy Development during Ofatumumab Therapy for
Yu Hashimoto1,2, Takumi Tashiro1, Ryosuke Ogawa3
1Department of Neurology, Japan Community Health Care Organization Kyushu Hospital, Japan.
Abstract:
A 79-year-old man experienced cognitive impairment and visual field defects during ofatumumab therapy for chronic lymphocytic leukemia refractory to combination chemotherapy. Magnetic resonance imaging revealed T1-weighted low-intensity and T2-weighted high-intensity lesions with patchy gadolinium enhancement in the subcortical white matter. A diagnosis of progressive multifocal leukoencephalopathy was made after the detection of John Cunningham virus (JCV) DNA in his cerebrospinal fluid (CSF). Following plasma exchange and the administration of mirtazapine and mefloquine, the JCV DNA levels in the CSF decreased. However, the patient died 55 days after treatment was initiated. Ofatumumab treatment appears to be associated with the development of progressive multifocal leukoencephalopathy.
More Related Videos
Related Concept Videos
Treatment Resistant Cancers
Therapeutic Drug Monitoring: Affecting Factors

